Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
4
67%
Ph phase_2
2
33%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Terminated(1)

Detailed Status

Completed5
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (66.7%)
Phase 22 (33.3%)

Trials by Status

withdrawn117%
completed583%

Recent Activity

0 active trials
Showing 5 of 6
withdrawnphase_1

POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer

NCT04826016
completedphase_1

Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer

NCT01837095
completedphase_2

CXCR4 Antagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI)

NCT01905475
completedphase_1

Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies

NCT01413568
completedphase_1

Safety and Efficacy of POL6326 for Mobilization of Hematopoietic Stem Cells in Healthy Volunteers

NCT01841476
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04826016Phase 1

POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer

Withdrawn
NCT01837095Phase 1

Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer

Completed
NCT01905475Phase 2

CXCR4 Antagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI)

Completed
NCT01413568Phase 1

Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies

Completed
NCT01841476Phase 1

Safety and Efficacy of POL6326 for Mobilization of Hematopoietic Stem Cells in Healthy Volunteers

Completed
NCT01105403Phase 2

Exploratory Study on POL6326 in Stem Cell Mobilization

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6